
    
      SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by
      nivolumab 240 mg IV q 2wk until progression or intolerable toxicity
    
  